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Translational Relevance
Mutations in the p53 gene are present in the majority of solid tumors and result in high levels of p53 protein within tumor cells. In contrast, the concentration of wild type p53 in normal tissue is low. Hence p53 is an attractive target for immunotherapy of a wide range of malignancies, and data from in vitro studies, murine models and clinical trials support the rationale of targeting this protein. We conducted a first-in-human, Phase I trial of a Modified Vaccinia Ankara vector delivering wild type human p53 (p53MVA) in patients with refractory GI cancers. p53MVA was well tolerated and elevated the p53-specific CD8 + T cell response. Furthermore, higher anti-p53 immune responses were detected in patients with lower frequencies of PD-1 + T cells and enhanced responses were achievable with antibody blockade of PD-1 in vitro. These initial findings support the continued development of p53MVA, particularly in combination with immune checkpoint inhibition.
Introduction
Immune based therapies have been most extensively studied in cancers such as melanoma, but there is evidence that anti-tumour immune responses in gastrointestinal (GI) cancer patients correlate with improved prognosis (1, 2) . The obstacles to stimulating effective anti tumor immunity are considerable, but there is encouraging evidence that immunotherapy can improve outcomes in cancer patients (3) (4) (5) . Furthermore, it is now recognized that radiotherapy and some chemotherapy agents confer therapeutic benefit, at least partly, by stimulating immune responses that directly target cancer cells or induce immunostimulatory side effects (6) .
Wild type p53 protein maintains normal cell division and mutations in this gene are present in the majority of solid tumors (7) . p53 gene mutations result in the accumulation of high levels of oncogenic p53 protein within tumor cells. In contrast, the concentration of normal p53 in healthy cells is low, making p53 an attractive target for immunotherapy of a wide range of malignancies. Immune recognition of p53 in tumor cells has been demonstrated both in vitro (8, 9) and in mouse models (10, 11) . Furthermore, clinical trials targeting p53 by administration of synthetic peptides and dendritic cell based vaccines have yielded promising results (12, 13) . Most notable are trials utilizing dendritic cells infected with a p53 adenoviral vector (Advexin), which showed evidence of clinical benefit when administered to lung cancer patients (14) . However the p53 vaccines tested to date are restricted to patients with certain tissue types, or require individual manufacture for each recipient and hence are laborious and costly to produce.
We have developed a strategy using the genetically engineered version of the MVA virus (Modified Vaccinia Ankara) to immunize patients with the wild type p53 antigen (p53MVA).
Using a viral vector to deliver full-length p53 has the potential to generate sustained antigen expression and the presentation of numerous antigenic determinants on different HLA
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molecules. In pre-clinical studies, Hupki mice (Human p53 Knock-In) were engineered to substitute the mouse p53 gene with the human form, enabling tolerance, thereby developing an immunological milieu similar to what the human vaccine will encounter clinically. Hupki mice immunized with p53MVA showed regression of established 4TI syngeneic breast tumors with murine p53 knockout and engineered human p53 expression, and generation of systemic anti-tumor immunity (15) . Finally, studies with PBMC collected from cancer patients with solid tumors showed that specific recall immune responses to p53 could be stimulated in vitro with p53MVA (16) .
MVA has a demonstrated safety record, being used in numerous clinical trials with only mild side-effects. The initial vaccine dose of 1.0 x 10 8 pfu was chosen because a previous trial using MVA expressing IL-2 and MUC1 reported low toxicity, as well as disease stabilization and cellular immune responses (17) . In the MVA-5T4 trials for colorectal cancer which used doses of 5.0 x 10 8 pfu, immunological and clinical responses were achieved in the absence of toxicity (18) . Murine studies conducted by us (10) and others (19) have demonstrated that p53 based immunotherapy is most effective when used in combination with anti-CTLA4.
Furthermore, comparable human data was reported in prostate cancer patients treated with a combination of a PSA-fowlpox vaccine and ipilimumab TM (Bristol-Myers Squibb, New York City, NY) (20) . This adds weight to the rationale of combining viral based vaccines with other immunostimulatory agents. However, since this was a first-in-human trial of p53MVA, a single agent study was optimal to assess properties of the vaccine construct. Here we report the findings of this study in regard to safety, clinical response and immunological endpoints.
Methods

p53MVA Vaccine Formulation
The therapeutic agent tested in this study was a Modified Vaccinia Ankara vector expressing full length wild type human p53. The p53MVA vaccine product was manufactured at the Center for Biomedicine and Genetics at City of Hope using GMP-grade materials and the final formulation was diluted in phosphate-buffered saline (PBS) and 7.5% lactose. The p53MVA vaccine was previously evaluated in an IND-directed toxicology study in mice.
There was no significant toxicity in terms of weight loss, physical exam, activity level, or chemical or hematologic studies (data not shown). p53MVA was vialed at two different concentrations, 1.3 x 10 8 pfu/ml and 7.0 x 10 8 pfu/ml and stored at -80 o C. Vaccine doses were thawed at room temperature and administered within 1 hour of thawing. Previous studies showed that the vaccine was stable at room temperature for 4 hours (data not shown).
Patients received injections in a volume of 0.8ml. There were no other therapeutic products involved.
Patients and Eligibility Criteria
Participants were recruited from GI cancer patients attending Medical Oncology clinics at the Table 1 .
Dose Escalation
The study included 12 patients treated at escalating doses of 1. 
Clinical Procedure
Phlebotomy was performed for biochemical, hematological and immunological assays prior to vaccination and two weeks following each immunization according to the schedule shown (Fig 1) . A CT scan and physical exam were carried out pre-study to establish the extent of disease and was repeated two months following the initial injection. Vaccine injections were administered by a study nurse in the subcutaneous tissue of the upper arm over the deltoid muscle on days 0, 21 and 42. All subjects were monitored for one hour in the clinic after each immunization for temperature changes and local reactions at the injection site. All subjects were contacted 24 and 48 hours after each immunization in order to record any vaccine related complications. Two patients were unable to complete the vaccination schedule due to disease progression, but all 12 enrolled patients provided a pre and postvaccine blood draw for immunological analysis.
Cell Culture
Peripheral blood samples were collected from patients by venipuncture in ACD tubes and processed within an hour. PBMCs were purified by density gradient separation using 
Measurement of T cell activation:
Cells from each in vitro stimulation were co-stained with anti-CD4, anti-CD8 and anti CD137-PE or a PE-labelled isotype control. CD137 positivity was assessed relative to the isotype control PE signal. Flow cytometric analyses were carried out using a FACSCanto (BD Biosciences) or Gallios TM (Beckman Coulter) flow cytometer.
All data was analysed with Flowjo7.5.6.
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MVA Neutralisation Assays
Plasma was obtained by centrifugation of whole blood for 10 minutes, at room temperature for 1500 rpm. Aliquots were frozen and stored at -80 o C until analysis. A modified version of the protocol described in Cosma et al 2004 (21) was used to assess the ability of patient plasma to neutralize MVA. Plasma samples were heat treated for 30 minutes at 56°C to inactivate complement, then cooled. Serial dilutions of plasma from 1:10-1:1000 were prepared in RPMI 1640 (Cellgro) with 10% fetal calf serum, to which was added 1 x 10 6 pfu of VenusMVA (previously described (22)). After 90 minutes incubation at 37°C, the different infection media were added to Hela cell monolayers and incubated for a further 2 hours. Plasma samples from Patient 3 were found to be unevaluable by this assay.
IFN-γ ELISPOT assays
Whole thawed PBMC or stimulated effector cells, were washed and seeded at 2 × 10 5 per well into ELISPOT plates coated with IFN-γ capture antibody as per the manufacturer's instructions (BD Biosciences). VenusMVA at an MOI of 0.2 was added to triplicate wells.
Additional control wells; media alone and PMA + Ionomycin or PHA were included to assess
Research. the background stimulation and viability of T cells respectively. Plates were incubated for 24 hours at 37°C, 5% CO 2 , after which cells were removed and the wells washed with distilled water. IFN-γ spots were visualized according to the manufacturer's instructions and counted by computer-assisted video image analysis using an AID ELISPOT reader (Autoimmun Diagnostka GmbH, Germany).
Statistical Analysis
The comparison of experimental values before and after immunization was evaluated using paired t-test. A two group t-test was used to compare the endpoint values between patients and healthy controls. The correlation between two normally distributed endpoints was evaluated using Pearson correlation analysis. Since all study endpoints consistently showed normality patterns, the use of parametric methods was considered more appropriate than nonparametric tests. P values less than 0.05 were considered significant and less than 0.005 as highly significant.
Research. Table 1 ). Figure 2B shows the peak response detected after vaccination compared to the pre-vaccine value in the CD4 + and CD8 + compartments. The initial dose of 1.0 x 10 8 pfu was not predicted to be therapeutic but some enhanced p53-immune reactivity were detected in these three patients, most notably in the CD8 + T cells from Patient 1.
However, in most cases, the frequency of p53-reactive T cells was comparable to that detected using PBMC from unvaccinated, healthy controls.
Vaccine enhanced p53-immune reactivity was higher in the patient cohort receiving the 5.6 x 10 8 pfu dose of p53MVA. This was most striking in the CD8 + T cell compartment. Figure 3A shows a representative flow cytometry plot from Patient 7. As with the low dose patient cohort, background stimulation was apparent, but even after subtraction of the CD137 signal from an irrelevant peptide, an enhancement of CD8 + p53 reactivity was significant after the first vaccination. This was seen in the majority of the high dose patients, and reached statistical significance (p=0.03). Furthermore, when the highest p53-specific responses detected post vaccination (peak response) were compared to pre vaccine levels, significance was even higher (p=0.002) in the CD8 + compartment. Despite the p53 peptide library containing both CD4 and CD8 epitopes, the increased p53 reactivity in the CD4 + compartment was less apparent in the CD8 + population and did not reach statistical significance (Fig 3B) . The expansion of p53-reactive CD8 + T cells was greatest after the first vaccination, and subsequent immunizations did not further amplify the response in the majority of patients.
p53MVA Vaccination Stimulates Strong anti Vector Immune Responses
A VenusMVA vector was used to assess the humoral and T cell response to the MVA backbone pre and post-vaccine in the low dose cohort and the first three patients of the high dose cohort. Figure 4 shows the anti-MVA T cell response as measured by IFN-γ ELISPOT Interestingly, in 5 out of 9 of the high dose cohort the frequency of MDSC in the peripheral blood declined after vaccination, however in many cases this was a transient effect.
Supplementary Figure 1C shows a representative example of the MDSC decline in Patient 6.
However, when analyzed as a group, the difference in MDSC frequency pre-and postimmunization did not reach statistical significance (Supplementary Fig 1B) .
The Frequency of PD-1 + CD8 + T cells is Greater in Patients than Healthy Controls and Shows a Correlation with p53 Response
The negative T cell co-stimulatory molecule PD-1, is exploited by tumor cells to evade immune clearance. The percentages of PD-1 + T cells detected in trial participants PBMC were significantly higher than in healthy controls (Fig 5A and B) . This was statistically 
Discussion
In this report we describe the first in human clinical trial of p53 delivered by an MVA vector in patients with advanced, refractory GI malignancies. Clinical and immunological responses were assessed, but the primary endpoint was safety. p53MVA was well tolerated in all 12
patients, causing only low grade side-effects ( Table 1 
populations respectively (26) . Tregs also exhibit some heterogeneity, with two main subtypes being recognized, natural Tregs generated during thymic development and inducible Tregs that arise in the periphery after interaction with tolerogenic stimuli. Tregs are crucial in maintaining peripheral tolerance to self antigens, and hence dampen effector T cell responses against many tumor antigens (31) . These suppressive cell types pose an obstacle to effective anti-tumor immunity, with both Tregs (32) and MDSC (33) being shown to affect vaccine induced immune responses. Hence, we thought it valuable to assess the frequency of these suppressive cells in the participants both pre-and post-vaccine. In 4/9 of the high dose patients, the frequency of MDSC increased slightly during the vaccination, concurrent with disease progression. However in 5/9 of the high dose cohort, the frequency of MDSC fell transiently after the first immunization ( Figure S1 ). Tregs also showed a slight downwards trend after immunization, but did not reach statistical significance ( Figure S2 lower panel) . In addition, the small sample size and the fact that both Treg and MDSC frequency were in the range for healthy donors, makes it difficult to attribute disease relatedness to these findings.
Detection of p53 specific T cells required an in vitro re-stimulation to expand them to detectable levels, a finding reported by other groups developing p53 targeted therapies (13, 34) . In order to ensure that is not a purely in vitro effect (in vitro immunization), healthy donor controls were included for comparison. The levels of p53 reactive T cells were generally lower than the responses seen in patients from the low dose cohort ( Figure 2B ).
Vaccine induced responses were of greater magnitude in the high dose cohort, particularly with regard to CD8 + responses. 7/9 patients in the high dose cohort showed increased p53 reactive CD4 + T cells post vaccination, the median fold increase being 3.5 ( Figure 3B chemotherapy has also shown promise in GI cancer patients (18, 49) , which raises another possible combination for p53MVA vaccine therapy.
In conclusion, it is likely that the high levels of immunosuppression in this patient group were a barrier to achieving objective clinical responses from p53MVA immunization. However, the tolerability profile and the ability to elevate the p53-specific CD8 + T cell response, 
